How long did you take this medication to work?
Actions of Durathate in details
Pharmacotherapeutic Group: Androgens, 3-oxoandrosten (4) derivatives. ATC Code: G03BA03.
Pharmacology: Pharmacodynamics: Durathate undecanoate is an ester of the naturally occurring androgen, Durathate. The active form, Durathate, is formed by cleavage of the side chain.
Durathate is the most important androgen of the male, mainly synthesized in the testicles, and to a small extent in the adrenal cortex.
Durathate is responsible for the expression of masculine characteristics during fetal, early childhood, and pubertal development and thereafter for maintaining the masculine phenotype and androgen-dependent functions (eg, spermatogenesis, accessory sexual glands). It also performs functions eg, in the skin, muscles, skeleton, kidney, liver, bone marrow and CNS.
Dependent on the target organ, the spectrum of activities of Durathate is mainly androgenic (eg, prostate, seminal vesicles, epididymis) or protein-anabolic (muscle, bone, hematopoiesis, kidney, liver).
The effects of Durathate in some organs arise after peripheral conversion of Durathate to estradiol, which then binds to estrogen receptors in the target cell nucleus eg, the pituitary, fat, brain, bone, and testicular Leydig cells.
Pharmacokinetics: Absorption: Durathate is an IM administered depot preparation of Durathate undecanoate and thus circumvents the first-pass effect. Following IM injection of Durathate undecanoate as an oily solution, the compound is gradually released from the depot and is almost completely cleaved by serum esterases into Durathate and undecanoic acid. An increase in serum levels of Durathate above basal values may be seen 1 day after administration.
Steady-State Conditions: After the 1st IM injection of Durathate undecanoate 1000 mg to hypogonadal men, mean Cmax values of 38 nmol/L (11 ng/mL) were obtained after 7 days. The 2nd dose was administered 6 weeks after the 1st injection and maximum Durathate concentrations of about 50 nmol/L (15 ng/mL) were reached. A constant dosing interval of 10 weeks was maintained during the following 3 administrations and steady-state conditions were achieved between the 3rd and the 5th administration. Mean Cmax and Cmin values of Durathate at steady state were about 37 (11 ng/mL) and 16 nmol/L (5 ng/mL), respectively. The median intra- and inter-individual variability (coefficient of variation, %) of Cmin values was 22% (range: 9-28%) and 34% (range: 25-48%), respectively.
Distribution: In serum of men, about 98% of the circulating Durathate is bound to sex hormone binding globulin (SHBG) and albumin. Only the free fraction of Durathate is considered as biologically active. Following IV infusion of Durathate to elderly men, the elimination half-life of Durathate was approximately 1 hr and an apparent volume of distribution of about 1 L/kg was determined.
Metabolism: Durathate which is generated by ester cleavage from Durathate undecanoate is metabolized and excreted the same way as endogenous Durathate. The undecanoic acid is metabolized by β-oxidation in the same way as other aliphatic carboxylic acids. The major active metabolites of Durathate are estradiol and dihydrotestosterone.
Elimination: Durathate undergoes extensive hepatic and extrahepatic metabolism. After the administration of radiolabeled Durathate, about 90% of the radioactivity appears in the urine as glucuronic and sulfuric acid conjugates and 6% appears in the feces after undergoing enterohepatic circulation. Urinary medicinal products include androsterone and etiocholanolone. Following IM administration of this depot formulation the release rate is characterized by a half-life of 90±40 days.
Toxicology: Preclinical Safety Data: Toxicological studies have not revealed other effects than those which can be explained based on the hormone profile of Durathate.
Durathate has been found to be nonmutagenic in vitro using the reverse mutation model (Ames test) or hamster ovary cells. A relationship between androgen treatment and certain cancers has been found in studies on laboratory animals. Experimental data in rats have shown increased incidences of prostate cancer after treatment with Durathate.
Sex hormones are known to facilitate the development of certain tumors induced by known carcinogenic agents. The clinical relevance of the latter observation is not known.
Fertility studies in rodents and primates have shown that treatment with Durathate can impair fertility by suppressing spermatogenesis in a dose-dependent manner.
How should I take Durathate?
This section provides information on the proper use of a number of products that contain Durathate. It may not be specific to Durathate. Please read with care.
This medicine comes with a Medication Guide and patient instructions. Read and follow these instructions carefully. Ask your doctor if you have any questions.
Durathate® or Fortesta® is available in two forms: individual packets or multi-dose pump. Vogelxo™ is available in three forms: individual packets, multi-dose pump, or tube. If you are using the pump gel for the first time, prime the pump before measuring out your first dose. Hold the pump over a sink and press the pump all the way down at least 3 times (Durathate® or Vogelxo™) or 8 times (Fortesta®) or until the gel begins to flow freely. Rinse the medicine discarded into the sink down the drain. Place the palm of your hand under the pump and press the pump the proper number of times to measure out your correct dose.
If you are using the gel in foil packets, tear the packet completely open along the perforation. Squeeze the entire contents directly onto the skin where you will apply the gel. You may also empty the packet into the palm of your hand and then apply the medicine. Throw away the empty foil packet in a place where children and pets cannot reach it.
Durathate® is available in two dosage strengths: Durathate® 1% and Durathate® 1.62%. Durathate® 1% is used differently than Durathate® 1.62%, even though they are both applied to the skin. Do not change your dose unless your doctor tells you to.
To use the gel:
- Make sure that you wash your hands with soap and water before and after applying the gel.
- Apply Durathate® 1% to a clean, dry, intact skin of the shoulders, upper arms, or abdomen (stomach), unless your doctor tells you to use it on another part of your body. Durathate® 1.62% should only be applied to a clean, dry intact skin of the shoulders and upper arms. Fortesta® should be applied to a clean, dry, intact skin of the front or inner thighs. Vogelxo™ should be applied to a clean, dry, intact skin of the shoulders or upper arms. Do not apply Vogelxo™ to your abdomen or stomach. Do not apply this medicine to your scrotum or your penis. Do not use the medicine on skin that has a cut, scrape, or other type of injury.
- Allow the gel to dry on your skin before you cover it with clothing (eg, shorts, pants, t-shirt).
- Wait for at least 2 hours (for Durathate® 1.62%, Fortesta®, and Vogelxo™) or 5 hours (for Durathate® 1%) after applying this medicine before showering or swimming.
The gel form can be transferred to another person if they touch or rub the skin where the gel was placed or if some of the gel remains on your hands. To keep this from happening, wash your hands again after applying the gel. Also, wash the area where you applied the gel with soap and water if you expect to have a skin-to-skin contact with another person.
This medicine is flammable until it dries on the skin. Do not use it near heat, an open flame, or while smoking.
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
- For topical dosage form (gel):
- For hormone replacement:
- Durathate® 1%: At first, apply 5 grams to a clean, dry, intact skin once a day (usually in the morning). Your doctor may increase your dose as needed. However, the dose is usually not more than 10 grams.
- Durathate® 1.62%: At first, apply 40.5 milligrams (mg) (two pumps or a single 40.5 mg packet) to a clean, dry, intact skin once a day (usually in the morning). Your doctor may adjust your dose as needed. However, the dose is usually not more than 81 mg per day.
- Fortesta®: At first, apply 40 milligrams (mg) (four pumps) to a clean, dry, intact skin once a day (usually in the morning). Your doctor may adjust your dose as needed. However, the dose is usually not more than 70 mg per day.
- Vogelxo™: At first, apply 50 milligrams (mg) (one tube, one packet, or four pumps) to a clean, dry, intact skin once a day (usually in the morning). Your doctor may adjust your dose as needed. However, the dose is usually not more than 100 mg once a day.
- Children—Use and dose must be determined by your doctor.
- For hormone replacement:
If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Use Durathate buccal system exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
To use the Durathate buccal system (Durathate):
- Hold one buccal system with the flat side on your fingertip. Place the curved side onto your gum, as high as possible above the left or right incisor tooth. Hold your finger on the outside of your lip over the system for 30 seconds to ensure the system is attached to the gum. If the system sticks to the cheek and not the gum, this is acceptable.
- The buccal system should remain in place for 12 hours. To remove the system, move it slightly toward the back or front of the mouth then slide it toward the teeth from removal. With each new application, rotate to alternate sides of the mouth. This avoids scratching the gum. Check to see that the system is in place after eating, drinking, brushing the teeth, or using mouthwash.
- As the buccal system absorbs moisture from the mouth, it will begin to soften and will mold to the shape of the gum. The system does not dissolve completely, but will remain in place. It will not move until you remove it.
- If a buccal system falls off before 8 hours of use, remove it and replace it with a new system in the same place.
- Change the buccal system and alternate sides of the mouth 12 hours after application of the original system. If a buccal system falls off after 8 hours but before 12 hours of use, remove the system and replace it with a new system above the opposite incisor. This will serve as the second dose for the day.
- Do not chew or swallow the Durathate buccal system.
- Regularly inspect the gum where the Durathate buccal system is applied. Promptly report any changes to your doctor or dentist.
Your doctor may want to perform tests to monitor the amount of Durathate in the body, liver function, prostate function, cholesterol levels, or other factors during treatment with Durathate buccal system.
It is important to use Durathate buccal system regularly to get the most benefit.
Dispose of all used systems properly, out of the reach of children and pets.
Store Durathate buccal system at room temperature away from moisture and heat.
Mechanism of Action
Endogenous androgens, including Durathate and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal chord thickening, alterations in body musculature and fat distribution. Durathate and DHT are necessary for the normal development of secondary sex characteristics.
Male hypogonadism, a clinical syndrome resulting from insufficient secretion of Durathate, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter’s syndrome or Leydig cell aplasia, whereas secondary hypogonadism is the failure of the hypothalamus (or pituitary) to produce sufficient gonadotropins (FSH, LH).
No specific pharmacodynamic studies were conducted using Durathate 1%.
Durathate 1% delivers physiologic amounts of Durathate, producing circulating Durathate concentrations that approximate normal concentrations (298 - 1043 ng/dL) seen in healthy men. Durathate 1% provides continuous transdermal delivery of Durathate for 24 hours following a single application to intact, clean, dry skin of the shoulders, upper arms and/or abdomen.
Durathate 1% is a hydroalcoholic formulation that dries quickly when applied to the skin surface. The skin serves as a reservoir for the sustained release of Durathate into the systemic circulation. Approximately 10% of the Durathate dose applied on the skin surface from Durathate is absorbed into systemic circulation. In a study with Durathate 1% 100 mg, all patients showed an increase in serum Durathate within 30 minutes, and eight of nine patients had a serum Durathate concentration within normal range by 4 hours after the initial application. Absorption of Durathate into the blood continues for the entire 24-hour dosing interval. Serum concentrations approximate the steady-state concentration by the end of the first 24 hours and are at steady state by the second or third day of dosing.
With single daily applications of Durathate 1%, follow-up measurements 30, 90 and 180 days after starting treatment have confirmed that serum Durathate concentrations are generally maintained within the eugonadal range. Figure 1 summarizes the 24-hour pharmacokinetic profiles of Durathate for hypogonadal men (less than 300 ng/dL) maintained on Durathate 1% 50 mg or 100 mg for 30 days. The average (± SD) daily Durathate concentration produced by Durathate 1% 100 mg on Day 30 was 792 (± 294) ng/dL and by Durathate 1% 50 mg 566 (± 262) ng/dL.
Figure 1: Mean (± SD) Steady-State Serum Durathate Concentrations on Day 30 in Patients Applying Durathate 1% Once Daily
Circulating Durathate is primarily bound in the serum to sex hormone-binding globulin (SHBG) and albumin. Approximately 40% of Durathate in plasma is bound to SHBG, 2% remains unbound (free) and the rest is bound to albumin and other proteins.
Durathate is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of Durathate are estradiol and dihydrotestosterone (DHT).
DHT concentrations increased in parallel with Durathate concentrations during Durathate 1% treatment. The mean steady-state DHT/T ratio during 180 days of Durathate treatment ranged from 0.23 to 0.29 (50 mg of Durathate 1%/day) and from 0.27 to 0.33 (100 mg of Durathate 1%/day).
There is considerable variation in the half-life of Durathate concentration as reported in the literature, ranging from 10 to 100 minutes. About 90% of a dose of Durathate given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of Durathate and its metabolites. About 6% of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of Durathate occurs primarily in the liver.
When Durathate 1% treatment is discontinued after achieving steady state, serum Durathate concentrations remain in the normal range for 24 to 48 hours but return to their pretreatment concentrations by the fifth day after the last application.
Durathate Transfer from Male Patients to Female Partners
The potential for dermal Durathate transfer following Durathate 1% use was evaluated in a clinical study between males dosed with Durathate 1% and their untreated female partners. Two (2) to 12 hours after application of 100 mg of Durathate administered as Durathate 1% by the male subjects, the couples (N = 38 couples) engaged in daily, 15-minute sessions of vigorous skin-to-skin contact so that the female partners gained maximum exposure to the Durathate 1% application sites. Under these study conditions, all unprotected female partners had a serum Durathate concentration >2 times the baseline value at some time during the study. When a shirt covered the application site(s), the transfer of Durathate from the males to the female partners was completely prevented.
- DailyMed. "TESTOSTERONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- NCIt. "Therapeutic Testosterone: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
- EPA DSStox. "Testosterone: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Durathate are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Durathate. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported administrationNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology